Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis

Leukemia and Lymphoma

Volumn 57, Issue 10, 2016, Pages 2464-2467

  Al Ali, Haifa Kathrin ^a   Stalbovskaya, Viktoriya ^b   Gopalakrishna, Prashanth ^b   Perez Ronco, Julian ^b   Foltz, Lynda ^c  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RUXOLITINIB; PYRAZOLE DERIVATIVE;

ANEMIA; CANCER CHEMOTHERAPY; ERYTHROPOIESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; MEGAKARYOPOIESIS; MYELOFIBROSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT RESPONSE; COMPLICATION; DRUG EFFECTS; FEMALE; MALE; MORTALITY; MYELOID METAPLASIA; ORGAN SIZE; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SPLEEN; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANEMIA; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HEMOGLOBINS; HUMANS; MALE; ORGAN SIZE; PRIMARY MYELOFIBROSIS; PROGNOSIS; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPLEEN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84959244247     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2016.1146950     Document Type: Letter

References (11)

1. F.Cervantes, A.M.Vannucchi, J.J.Kiladjian, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122:4047–4053.
2. S.Verstovsek, R.A.Mesa, J.Gotlib, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis:results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100:479–488.
3. C.Harrison, J.J.Kiladjian, H.K.Al-Ali, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–798.
4. C.Sarr, S.Urva, J.Nedelman, et al. Mathematical modeling of patient-level hemoglobin delineates ruxolitinib’s complex mechanism of action and quantifies anemia risk. Blood. 2014;124(Suppl). Abstract no. 3228.
5. F.Cervantes, B.Dupriez, A.Pereira, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood. 2009;113:2895–2901.
6. F.Passamonti, F.Cervantes, A.M.Vannucchi, et al. A dynamic prognostic model to predict survival in primary myelofibrosis:a study by the IWG-MRT (international working group for myeloproliferative neoplasms research and treatment). Blood. 2010;115:1703–1708.
7. S.Verstovsek, R.A.Mesa, J.Gotlib, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.
8. A.M.Vannucchi, H.M.Kantarjian, J.J.Kiladjian, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100:1139–1145.
9. M.Breccia, M.Molica, G.Colafigli, et al. Improvement of bone marrow fibrosis with ruxolitinib:will this finding change our perception of the drug? Expert Rev Hematol. 2015;8:387–389.
10. H.M.Kvasnicka, J.Thiele, C.Bueso-Ramos, et al. Ruxolitinib induced modulation of bone marrow microenvironment in patients with myelofibrosis is associated with inflammatory cytokine levels. Blood. 2014;124(Suppl). Abstract no. 3182.
11. R.A.Mesa, J.Cortes Optimizing management of ruxolitinib in patients with myelofibrosis:the need for individualized dosing. J Hematol Oncol. 2013;6:79.